{"id":1384,"date":"2020-08-20T21:14:00","date_gmt":"2020-08-20T21:14:00","guid":{"rendered":"https:\/\/navyblue.bcmultistaging.wpenginepowered.com\/?p=1384"},"modified":"2026-05-15T17:30:49","modified_gmt":"2026-05-15T17:30:49","slug":"bespoke-immune-cells-ability-prevent-transplant-rejection","status":"publish","type":"post","link":"https:\/\/www.bcchr.ca\/levingslab\/2020\/08\/20\/bespoke-immune-cells-ability-prevent-transplant-rejection\/","title":{"rendered":"New study helps improve bespoke immune cells\u2019 ability to prevent transplant rejection in patients with donated tissue"},"content":{"rendered":"<p class=\"fndry-paragraph fndry-text-intro22\">A new study, published this week in\u00a0<em><a href=\"https:\/\/stm.sciencemag.org\/content\/12\/557\/eaaz3866\" target=\"_blank\" rel=\"noreferrer noopener\">Science Translational Medicine<\/a><\/em>, further refines a potential new treatment that can prevent transplant rejection in kids and adults without leaving them vulnerable to infection.<\/p>\n\n<p class=\"fndry-paragraph\">The treatment,\u00a0which was initially developed by <a href=\"https:\/\/www.bcchr.ca\/research\/find-a-researcher\/megan-levings\/\">Dr. Megan Levings\u2019<\/a> research team, involves genetically engineering specialized immune cells called T regulatory cells (T regs) so that they can dampen down the immune system if it mounts an overzealous response to transplanted tissues.\u00a0<\/p>\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><\/p>\n<\/blockquote>\n\n\n\n<div class=\"wp-block-media-text has-media-on-the-right is-stacked-on-mobile\" style=\"grid-template-columns:auto 25%\"><div class=\"wp-block-media-text__content\">\n<p class=\"wp-block-paragraph\">\u201cThe problem that patients face when receiving a donor organ is that their immune system is designed to recognize cells or tissues from another person as dangerous and attack them,\u201dsays senior author&nbsp;Dr. Levings. \u201cThe current solution to this problem is to use immunosuppressive drugs, but these medications can leave patients more vulnerable to subsequent infections or cancer.\u201d<\/p>\n<\/div><figure class=\"wp-block-media-text__media\"><img loading=\"lazy\" decoding=\"async\" width=\"600\" height=\"900\" src=\"https:\/\/www.bcchr.ca\/levingslab\/files\/2025\/01\/megan-levings-web.jpg\" alt=\"\" class=\"wp-image-2369 size-full\" srcset=\"https:\/\/www.bcchr.ca\/levingslab\/files\/2025\/01\/megan-levings-web.jpg 600w, https:\/\/www.bcchr.ca\/levingslab\/files\/2025\/01\/megan-levings-web-200x300.jpg 200w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/figure><\/div>\n\n\n<p class=\"fndry-paragraph\"><br>T regs have a natural ability to instruct the rest of the immune system to tone down or ignore a particular molecule. By inserting a gene into these cells, researchers can replace their targeting receptor with a designed one called CAR (chimeric antigen receptor). This new CAR can be tailored to recognize the donated tissue, and then orchestrate the rest of the immune system to leave it alone.<\/p>\n\n<p class=\"fndry-paragraph\">To boost these CAR T regs\u2019 ability to instruct other immune cells, the researchers in this study &nbsp;also tested additional genes that can further amplify this message to stand down.&nbsp;<\/p>\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><\/p>\n<\/blockquote>\n\n\n<div  class=\"fndry-container fndry-responsive-bg fndry-responsive-border fndry-pt--3 fndry-pb--3 fndry-pr--md-1 fndry-pl--md-1 fndry-pt--sm-0 fndry-pb--sm-0 fndry-mt--sm-3 fndry-mb--sm-3\">\n\t<div class=\"fndry-row\">\n\t<div  class=\"fndry-col fndry-responsive-bg fndry-col--12 fndry-col--sm-12 fndry-col--md-12 fndry-pl--sm-0\">\n\t<div  class=\"fndry-container fndry-responsive-bg fndry-responsive-border fndry-pt--3 fndry-pr--3 fndry-pb--3 fndry-pl--3 fndry-pt--sm-2 fndry-pr--sm-2 fndry-pb--sm-2 fndry-pl--sm-2\" style=\"--fndry-bg:var(--fndry-color-light)\">\n\t<figure  class=\"fndry-quote fndry-quote--left\">\n\t<blockquote class=\"fndry-quote__quote\">\n\t\t<p class=\"fndry-text-intro22\">&#8220;There are an enormous variety of cellular signals that collectively act as a circuit board to instruct immune cells to speed up, slow down, last longer or proliferate. So we created 10 different types of CAR T regs and each one activated a different signal &#8211; effectively flicking different switches on the circuit board.\u201d\u00a0<\/p>\t<\/blockquote>\n\t<figcaption  class=\"fndry-quote__citation\">\n\t\t&#8211; Dr. Megan Levings\t<\/figcaption>\n<\/figure><\/div>\n<\/div>\n<\/div><\/div>\n\n\n<p class=\"fndry-paragraph\">The research team then analyzed how well these different versions of CAR T regs performed using an animal model of graft versus host disease, a harmful immune response that can happen in bone marrow transplantation, as well as testing their ability to regulate immune signals.<\/p>\n\n<p class=\"fndry-paragraph\">The group found that CAR Tregs that specifically activated a signal called CD28 (which is required for T cell activation and survival) was the most effective at protecting the host from a harmful immune response.&nbsp;<\/p>\n\n<p class=\"fndry-paragraph\">\u201cThis method of engineering immune cells is still in the early phases of development, and the scientific community has only just scratched the surface of the various ways we can manipulate these cells to give a desired response,\u201d said Dr. Levings. \u201cTo ensure we are pursuing the right path, we systematically investigated several potential signals to ensure we\u2019re developing the best possible therapy for these patients.&#8221;<\/p>\n\n<div  class=\"fndry-container fndry-responsive-bg fndry-responsive-border fndry-pt--3 fndry-pb--3 fndry-pr--md-1 fndry-pl--md-1 fndry-pt--sm-0 fndry-pb--sm-0 fndry-mt--sm-3 fndry-mb--sm-3\">\n\t<div class=\"fndry-row\">\n\t<div  class=\"fndry-col fndry-responsive-bg fndry-col--12 fndry-col--sm-12 fndry-col--md-12 fndry-pl--sm-0\">\n\t<div  class=\"fndry-container fndry-responsive-bg fndry-responsive-border fndry-pt--3 fndry-pr--3 fndry-pb--3 fndry-pl--3 fndry-pt--sm-2 fndry-pr--sm-2 fndry-pb--sm-2 fndry-pl--sm-2\" style=\"--fndry-bg:var(--fndry-color-light)\">\n\t<figure  class=\"fndry-quote fndry-quote--left\">\n\t<blockquote class=\"fndry-quote__quote\">\n\t\t<p class=\"fndry-text-intro22\">&#8220;Once we\u2019re sure that we have designed the strongest possible candidate, we can pave the way for a future in which kids and adults needing organ transplants can receive them safely and without the need for immunosuppressive drugs and the resulting complications.\u201d<\/p>\t<\/blockquote>\n\t<figcaption  class=\"fndry-quote__citation\">\n\t\t&#8211; Dr. Megan Levings\t<\/figcaption>\n<\/figure><\/div>\n<\/div>\n<\/div><\/div>\n\n\n<p class=\"fndry-paragraph\">Dr. Levings is an investigator and head of the Childhood Disease Research Theme at BC Children\u2019s as well as a professor in UBC\u2019s Department of Surgery and School of Biomedical Engineering.<\/p>","protected":false},"excerpt":{"rendered":"<p>A new study, published this week in Science Translational Medicine, further refines a potential new treatment that can prevent transplant rejection in kids and adults without leaving them vulnerable to infection.<\/p>\n","protected":false},"author":2,"featured_media":2386,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","inline_featured_image":false,"footnotes":"","fndry_alternate_title":""},"categories":[10],"tags":[14,23,13,12],"class_list":["post-1384","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-immune-system","tag-regulatory-t-cells","tag-transplant","tag-tregs"],"modified_by":"Andrea Sakamoto","_links":{"self":[{"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/posts\/1384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/comments?post=1384"}],"version-history":[{"count":4,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/posts\/1384\/revisions"}],"predecessor-version":[{"id":2395,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/posts\/1384\/revisions\/2395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/media\/2386"}],"wp:attachment":[{"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/media?parent=1384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/categories?post=1384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bcchr.ca\/levingslab\/wp-json\/wp\/v2\/tags?post=1384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}